Pharmacokinetics and bioequivalence study of Gliclazide tables in Chinese healthy volunteers
Tan Heng-sha
Abstract
Tan Heng-sha
Abstract
Objective To study the relative bioavailability and bioequivalence of Gliclazide tables (test) to the normal tables (reference) in Chinese healthy volunteers. Methods 20 male healthy volunteers were randomized to receive a single crossover oral dose of 80 mg test tables or reference tables.The plasma concentration of Gliclazide was determined by HPLC method. Results The method was linear in the 0.104~12.48 μg/ml concentration range (r=0.999 88);The mean recovery rate was 90.125%~104.6%,the inter-day RSD and intra-day RSD were less 10%;The main pharmacokinetic parameters without significant difference of test and reference Gliclazide tables were as follows: Tmax:(4.4±0.9) and (4.0±0.9)h;Cmax:(4.8±0.6) and (5.3±0.8)mg/L;AUC0~48 h:(86±29) and (88±33)mg·L-1·h-1;AUC0~∞:(99±45) and (103±58)mg·L-1·h-1;T1/2:(13±4) and (14±5)h,F0~48 h was(99±9)%. Conclusion The test Gliclazide tables were bioequivalent to the reference tables.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To study the relative bioavailability and bioequivalence of Gliclazide tables (test) to the normal tables (reference) in Chinese healthy volunteers. Methods 20 male healthy volunteers were randomized to receive a single crossover oral dose of 80 mg test tables or reference tables.The plasma concentration of Gliclazide was determined by HPLC method. Results The method was linear in the 0.104~12.48 μg/ml concentration range (r=0.999 88);The mean recovery rate was 90.125%~104.6%,the inter-day RSD and intra-day RSD were less 10%;The main pharmacokinetic parameters without significant difference of test and reference Gliclazide tables were as follows: Tmax:(4.4±0.9) and (4.0±0.9)h;Cmax:(4.8±0.6) and (5.3±0.8)mg/L;AUC0~48 h:(86±29) and (88±33)mg·L-1·h-1;AUC0~∞:(99±45) and (103±58)mg·L-1·h-1;T1/2:(13±4) and (14±5)h,F0~48 h was(99±9)%. Conclusion The test Gliclazide tables were bioequivalent to the reference tables.
Key concepts: Bioequivalence, Gliclazide, Cmax, Pharmacokinetics, Bioavailability, Crossover study, Medicine, Pharmacology